Pete is Co-Founder, President and CEO of Remix Therapeutics. Prior to Remix, he was Chief Scientific Officer at H3 Biomedicine, a precision oncology company, where he oversaw discovery, non-clinical development, translational research and clinical biomarkers. He was previously at Takeda and Millennium Pharmaceuticals where he focused on oncology drug discovery and early clinical development. He is excited by Remix’s potential to treat a variety of diseases and disorders with their groundbreaking scientific approach to reprogramming RNA. He received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute. Pete also sits on the Board of Directors of Ryvu Therapeutics and is an advisor to several drug discovery companies.